<DOC>
	<DOCNO>NCT01488708</DOCNO>
	<brief_summary>The purpose SLE study evaluate long-term safety efficacy LY2127399 eligible SLE participant complete core study ( NCT01196091 ) ( NCT01205438 ) .</brief_summary>
	<brief_title>On Open-Label Study Participants With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have complete 52 week treatment core study ( NCT01196091 ) ( NCT01205438 ) Given write informed consent Test negative pregnancy time enrollment Agree use reliable method birth control Unwilling comply study procedures Any condition render participant unable understand nature scope possible consequence study Any condition opinion investigator pose unacceptable risk participant study drug would administer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Immune System Disease</keyword>
</DOC>